Decitabine 'better-tolerated alternative' to chemotherapy for older, fit patients with AML
Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates comparable to those treated with induction chemotherapy but with fewer toxicities, according to results of a randomized phase 3 study.“Ten-day decitabine provides a better-tolerated alternative to aggressive chemotherapy in older, fit patients with AML,” Michael Lübbert, MD, of